For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
1 August, 2024•10 min
0
1 August, 2024•10 min
0
More in Business
Business
Hero’s comeback has legs, but can it keep its grip?
India’s largest two-wheeler maker has seen a stock surge on the back of macro tailwinds, an EV push, a credible export strategy and renewed investor faith. Proving that this rally isn’t just a festive-season fling will be the real test.
You may also like
Business
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Health
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
